Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.47 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL28861229 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL440871 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL27499954 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL5309514 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL19030905 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL1564 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL28217483 | 0.97 | LMNA (0.44) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL29291744 | 0.97 | LMNA (0.44) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL28199975 | 0.97 | LMNA (0.44) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL27709522 | 0.97 | LMNA (0.44) | CA4FAHD1LMNATSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113818044-B | Preparation method of PtCu alloy catalyst for efficient electrocatalytic synthesis of ammonia | 西安交通大学 | 2022-10-25 | — | — | CN | claimed |
| CN-113818044-A | Preparation method of PtCu alloy catalyst for efficient electrocatalytic synthesis of ammonia | 西安交通大学 | 2021-12-21 | — | — | CN | claimed |
| CN-108872120-A | A kind of detection method of saliferous lidocaine hydrochloride medical cross-linking sodium hyaluronate gel protein content | 浙江景嘉医疗科技有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-103517920-B | Anti- hardened proteins (SCLEROSTIN) antibody crystals and its preparation | 安进公司 | 2018-04-17 | — | — | CN | claimed |
| CN-117328047-A | Rhodium-containing PCB substrate electroless plating activating solution and electroless plating method thereof | 电子科技大学 | 2024-01-02 | — | — | CN | disclosed |
| CN-113260692-B | Preparation method of graphene quantum dots | 迪恩孙(生物科技)股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11718531-B2 | Method for producing graphene quantum dots | DXOME CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| CN-113818044-B | Preparation method of PtCu alloy catalyst for efficient electrocatalytic synthesis of ammonia | 西安交通大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-113698402-B | Synthetic method and application of natural alkaloid Arbornamine with anti-inflammatory activity | 华南理工大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-113818044-A | Preparation method of PtCu alloy catalyst for efficient electrocatalytic synthesis of ammonia | 西安交通大学 | 2021-12-21 | — | — | CN | disclosed |
| CN-113698402-A | Synthetic method and application of natural alkaloid Arbornamine with anti-inflammatory activity | 华南理工大学 | 2021-11-26 | — | — | CN | disclosed |
| US-20210316995-A1 | METHOD FOR PRODUCING GRAPHENE QUANTUM DOTS | DXOME CO., LTD. (KR) | 2021-10-14 | — | — | US | disclosed |
| EP-1282596-A1 | PREPARATION OF IMINODIACETIC ACID COMPOUNDS FROM MONOETHANOLAMINE SUBSTRATES | Monsanto Technology LLC (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-1272451-A2 | PROCESS AND CATALYST FOR DEHYDROGENATING PRIMARY ALCOHOLS TO MAKE CARBOXYLIC ACID SALTS | Monsanto Technology LLC (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020161259-A1 | Process and catalyst for dehydrogenating primary alcohols to make carboxylic acid salts | MONSANTO COMPANY | 2002-10-31 | — | — | US | disclosed |
| US-6376708-B1 | USING COPPER, OR ALLOY THEREOF, AS CATALYST | MONSANTO TECHNOLOGY LLC | 2002-04-23 | — | — | US | disclosed |
| US-20020019564-A1 | Process and catalyst for dehydrogenating primary alcohols to make carboxylic acid salts | MONSANTO COMPANY | 2002-02-14 | — | — | US | disclosed |
| US-20020019565-A1 | Process for making iminodiacetic acid compounds from monoethanolamine substrates | MONSANTO TECHNOLOGY LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2001087827-A1 | PREPARATION OF IMINODIACETIC ACID COMPOUNDS FROM MONOETHANOLAMINE SUBSTRATES | MONSANTO TECHNOLOGY LLC (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001077054-A2 | PROCESS AND CATALYST FOR DEHYDROGENATING PRIMARY ALCOHOLS TO MAKE CARBOXYLIC ACID SALTS | MONSANTO TECHNOLOGY LLC (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161259-A1 | Process and catalyst for dehydrogenating primary alcohols to make carboxylic acid salts | ADH1A, ADH1C, ADH5 | CA4 185/4885FAHD1 2045/4885LMNA 4650/4885 |
| US-20020019565-A1 | Process for making iminodiacetic acid compounds from monoethanolamine substrates | INMT, NAAA, PNMT | CA4 637/4885FAHD1 1374/4885LMNA 703/4885 |
| US-20020019564-A1 | Process and catalyst for dehydrogenating primary alcohols to make carboxylic acid salts | ADH1A, ADH1C, ADH5 | CA4 66/4885FAHD1 3481/4885LMNA 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.